Sanofi, Regeneron report underwhelming data for IL-33 antibody itepekimab, shares drop
Sanofi and Regeneron on Friday reported lackluster late-stage results for their drug candidate in a common lung condition, leaving the partners to patch together a path forward. Their IL-33 targeting antibody, called itepekimab, achieved a ...
Sanofi and Regeneron on Friday reported lackluster late-stage results for their drug candidate in a common lung condition, leaving the partners to patch together a path forward.
Their IL-33 targeting antibody, called itepekimab, achieved a ...
